The primary objective consisted of avoiding deterioration and/or restoring the integrity of the skin of patients treated by radiotherapy, right from the first signs of grade 1 or 2 radiation dermatitis.

Inclusion Criteria:

• Women treated by normo fractionated radiotherapy for breast cancer
• Presenting grade 1 or 2 radiation dermatitis during the treatment and who provided their written informed consent were included in the study.

Exclusion criteria:

• Were male patients
• Radiation dermatitis already treated or caused by another treatment
• Subjects deprived of their freedom or under guardianship
• Subjects in whom medical follow-up was impossible
• A cancer wound or skin flap on the irradiated zone
• A history of allergic skin reaction
• Concomitant chemotherapy or concomitant bevacizumab therapy and bilateral irradiation.

Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies.

Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.

Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).